These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33856655)

  • 1. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
    Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
    Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
    Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
    Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
    Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
    Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
    Ramos M; Ustyugova A; Hau N; Lamotte M
    J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
    Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
    Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
    Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
    Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
    Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
    Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
    Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
    ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
    Shah D; Risebrough NA; Perdrizet J; Iyer NN; Gamble C; Dang-Tan T
    Clinicoecon Outcomes Res; 2018; 10():791-803. PubMed ID: 30532570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    Arbel R; Hammerman A; Azuri J
    Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
    Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.